钠-葡萄糖协同转运蛋白2抑制剂达格列净在肾移植合并糖尿病患者中的成功应用：病例系列及文献综述
Successful use of the sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with renal transplant and diabetes: a case series and literature review.
作者信息
Gul Wajiha, Naem Emad, Elawad Safa, Elhadd Tarik
机构信息
Department of Medicine, Endocrinology Section & Qatar Metabolic Institute, Hamad Medical Corporation.
Department of Medicine, Section of Nephrology, Hamad General Hospital, Doha, Qatar.
出版信息
Cardiovasc Endocrinol Metab. 2021 Mar 17;10(4):222-224. doi: 10.1097/XCE.0000000000000246. eCollection 2021 Dec.
UNLABELLED
Management of patients with diabetes and renal transplant could be challenging. Transplant patients use multiple immune suppressants that can worsen or even trigger hyperglycemia. There are no data about the use of the new class of sodium-glucose co-transporter-2 (SGLT-2) inhibitor dapagliflozin in patients with renal transplant and diabetes.
CASE SERIES
Four patients, with diabetes, who are attending the diabetes clinic at our institution, are presented here. They were all counseled to be started on dapagliflozin 10 mg to improve diabetes control as they were on multiple agents and not achieving targets. All four patients showed significant improvement in hemoglobin A1c, with no adverse effects on renal parameters and had favorable effect on weight and blood pressure (BP).
CONCLUSION
Use of the SGLT-2 inhibitor dapagliflozin in the standard dose of 10 mg helped to achieve satisfactory control with favorable effects on BP and weight with no adverse effects on renal function.
未标注
糖尿病合并肾移植患者的管理可能具有挑战性。移植患者使用多种免疫抑制剂，这些药物可能会加重甚至引发高血糖。目前尚无关于新型钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂达格列净在肾移植合并糖尿病患者中使用的数据。
病例系列
本文介绍了在我们机构糖尿病门诊就诊的4例糖尿病患者。由于他们使用多种药物但未达到目标，因此均接受了使用10毫克达格列净以改善糖尿病控制情况的建议。所有4例患者糖化血红蛋白均有显著改善，对肾脏参数无不良影响，对体重和血压（BP）有积极作用。
结论
使用标准剂量10毫克的SGLT-2抑制剂达格列净有助于实现满意的控制，对血压和体重有积极影响，对肾功能无不良影响。
Zotero 插件